Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
Authors
Harrold, Leslie R.John, Ani
Best, Jennie
Zlotnick, Steve
Karki, Chitra
Li, YouFu
Greenberg, Jeffrey D.
Kremer, Joel M.
Document Type
Journal ArticlePublication Date
2017-09-01Keywords
BiologicsPatient-reported outcomes
Rheumatoid arthritis
Rituximab
Immune System Diseases
Musculoskeletal Diseases
Rheumatology
Skin and Connective Tissue Diseases
Therapeutics
Metadata
Show full item recordAbstract
To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to > /=1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0-100); morning stiffness (hours); modified Health Assessment Questionnaire (mHAQ; 0-3); and EuroQoL EQ-5D. Of the 667 patients who newly initiated rituximab, baseline PRO and clinical measures indicated that patients were substantially impacted by their RA disease and quality of life; 54% of patients had high disease activity. One year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of patients reported clinically meaningful improvements in patient global, pain, fatigue, and mHAQ, respectively. Morning stiffness and EuroQol EQ-5D domains improved in 48 and 19-32% of patients, respectively. These real-world registry data demonstrated that patients with long-standing, refractory RA experienced improvements in PROs 1 year after initiating rituximab.Source
Clin Rheumatol. 2017 Sep;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2. Epub 2017 Jul 17. Link to article on publisher's siteDOI
10.1007/s10067-017-3742-2Permanent Link to this Item
http://hdl.handle.net/20.500.14038/40408PubMed ID
28718043Related Resources
Rights
© The Author(s) 2017. This article is an open access publication.Distribution License
http://creativecommons.org/licenses/by/4.0/ae974a485f413a2113503eed53cd6c53
10.1007/s10067-017-3742-2
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © The Author(s) 2017. This article is an open access publication.